Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT BuyoutBenzinga • 07/29/25
Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver DiseaseAccesswire • 07/29/25
Bausch + Lomb Announces Publication of Phase 3 Data on LUMIFY® Preservative Free Redness Reliever Eye DropsBusiness Wire • 07/29/25
Bausch Health Announces the Appointment of Two New Members to Its Board of DirectorsAccesswire • 07/24/25
CORRECTING and REPLACING: Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel), Now Available Through Public Drug Plans of Ontario, Nova Scotia and Two Federal ProgramsAccesswire • 07/10/25
Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel), Now Available Through Public Drug Plans of Ontario, Quebec and Two Federal ProgramsAccesswire • 07/09/25
Bausch Health's Gastroenterology Business, Salix Pharmaceuticals, Launches Fresh "I Wish I Knew" Campaign to Educate People About Xifaxan(R) (rifaximin) for Adults at Risk of Overt Hepatic Encephalopathy RecurrenceAccesswire • 07/07/25
Bausch + Lomb Announces Closing of Upsized €675 Million Senior Secured Notes Offering and Partial Credit Agreement Refinancing, Including Upsized $2.325 Billion Term Loan FacilityBusiness Wire • 06/26/25
Bausch Health Shares Rise as Nonexecutive Chairperson Paulson Buys $21.2M in SharesMarket Watch • 06/18/25
Bausch + Lomb Launches Blink® Nourish Lubricating Eye Drops and Blink Boost Lubricating Eye Drops in the United StatesBusiness Wire • 06/04/25
Facial Injectable Market Forecasts Report 2025-2030, Competitive Analysis of Key Players - Allergan, Bausch Health, Bloomage Biotechnology, and GaldermaGlobeNewsWire • 05/21/25